Dated: November 24, 2004 Signature: (Geograms Matos)	~ .	PTC-1390 (Rev. 10-2004) Approved for use through 03/31/2007 OMB 0651-0021	
U. S. Patent and Tra		Iemark Office; U.S. DEPARTMENT OF COMMERCE	
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  TRANSMITTAL LETTER TO THE UNITED STATES  ATTORNEY'S DOCKET NUMBER			
DESIGNATED/ELECTED OFFICE (D		404172000300	
CONCERNING A SUBMISSION UNDER		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
		10/511,229	
	AL FILING DATE	PRIORITY DATE CLAIMED	
	April 2002	None	
TITLE OF INVENTION PURIFIED SUBFRAGMENT CODIFYING FOR NEUROAMINIDASE, RECOMBINANT NEUROAMINIDASE AND ITS USE IN ZOOPROPHYLAXIS			
APPLICANT(S) FOR DO/EO/US Illaria CAPUA et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.			
This is a PROT submission of items concerning a submission under 35 0.3.c. 371.      This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.			
H 1			
This is an express request to begin national examination procedures (35 U.S.C. 371 (I)). The submission must include items (5), (6), (9) and (21) indicated below.			
4. The US has been elected (Article 31).			
A copy of the International Application as filed (35 U.S.C. 371 (c)(2))			
is attached hereto (required only if not communicated by the International Bureau).			
b. has been communicated by the International Bureau.			
c. Is not required, as the application was filed in the United States Receiving Office (RO/US).			
An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).			
a. is attached hereto.			
b. has been previously submitted under 35 U.S.C. 154(d)(4).			
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))			
a. are attached hereto (required only if not communicated by the International Bureau).			
b. have been communicated by the International Bureau.			
c. have not been made; however, the time limit for making such amendments has NOT expired.			
d. have not been made and will not be made.			
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).			
9. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).			
An English language translation of the annexes to the International Preliminary Examination Report under PCT  Article 36 (35 U.S.C. 371 (c)(5)).			
Items 11 to 20 below concern document(s) or information included:			
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. A preliminary amendment.			
4. An Application Data Sheet under 37 CFR 1.76.			
15. A substitute specification.			
6. A power of attorney and/or change of address letter.			
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.			
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).			
19. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).			
20. x Other items or information: Second Preliminary Amendment (6 pages); Return receipt postcard			
_			

page 1 of 2

PTO-1390 (Rev. 10-2004)
Approved for use through 03/31/2007 OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER U.S. APPLICATION NO. (if known, see 37 CFR 1.5) PCT/IT02/00231 10/511,229 404172000300 CALCULATIONS The following fees are submitted: PTO USE ONLY BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international Search Report not prepared by the EPO or JPO . . . . \$1110.00 ENTER APPROPRIATE BASIC FEE AMOUNT = 0.00 Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months 0.00 from the earliest claimed priority date (37 CFR 1.492 (e)). CLAIMS NUMBER FILED | NUMBER EXTRA RATE 14-20 = 18 00 0 00 Total claims n x Independent claims 2-3 = 88.00 0.00 MULTIPLE DEPENDENT CLAIM(s) (if applicable) 300.00 0.00 TOTAL OF ABOVE CALCULATIONS = 0.00 Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above 0.00 are reduced by 1/2. SUBTOTAL = 0.00 Processing fee of \$130.00 for furnishing the English translation later than 30 months 0.00 from the earliest claimed priority date (37 CFR 1.492 (f)). TOTAL NATIONAL FEE = 0.00 Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property 0.00 TOTAL FEES ENCLOSED = 0.00 Amount to be refunded: charged: A check in the amount of \$ to cover the above fees is enclosed Please charge my Deposit Account No. in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any . A duplicate copy of this sheet is enclosed. 03-1952 Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: SIGNATURE JUIN Leave Janet Xiao NAME 55.748 CUSTOMER NUMBER: 25226 REGISTRATION NUMBER

FORM PTO-1390 (REV 10-2004) pa-938026